300 results on '"Shaw, Wayne"'
Search Results
2. EW support for CENTCOM
3. Natriuretic Peptides and Prognosis in Patients With Type 2 Diabetes Mellitus and High Risk for Cardiovascular Events
4. Stress Cardiac Biomarkers, Cardiovascular and Renal Outcomes, and Response to Canagliflozin
5. Mediators of the Effects of Canagliflozin on Heart Failure in Patients With Type 2 Diabetes
6. Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials
7. Banks’ deferred tax assets during the financial crisis
8. Tax and Regulatory Motivations for Issuing Non-Voting, Non-Convertible Preferred Stock
9. Valuation of the Components of Purchased Goodwill
10. The Persistence of IPO Mispricing and the Predictive Power of Flipping
11. Impact of Age and Estimated Glomerular Filtration Rate on the Glycemic Efficacy and Safety of Canagliflozin: A Pooled Analysis of Clinical Studies
12. Effects of Canagliflozin on Heart Failure Outcomes Associated With Preserved and Reduced Ejection Fraction in Type 2 Diabetes Mellitus: Results From the CANVAS Program
13. Canagliflozin and Stroke in Type 2 Diabetes Mellitus: Results From the Randomized CANVAS Program Trials
14. Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS Program
15. Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study)
16. Fasting Substrate Concentrations Predict Cardiovascular Outcomes in the CANagliflozin cardioVascular Assessment Study (CANVAS)
17. The impact of accounting rule and economic differences on the firm’s choice of cash and share-puts
18. Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study–Renal (CANVAS‐R): A randomized, placebo‐controlled trial
19. Efficacy and Safety of Canagliflozin Used in Conjunction with Sulfonylurea in Patients with Type 2 Diabetes Mellitus: A Randomized, Controlled Trial
20. Association Between Circulating GDF‐15 and Cardio‐Renal Outcomes and Effect of Canagliflozin: Results From the CANVAS Trial
21. Efficacy and Safety of Canagliflozin in Individuals Aged 75 and Older with Type 2 Diabetes Mellitus: A Pooled Analysis
22. Canagliflozin: a sodium glucose co-transporter 2 inhibitor for the treatment of type 2 diabetes mellitus
23. Efficacy and Safety of Canagliflozin, an Inhibitor of Sodium–Glucose Cotransporter 2, When Used in Conjunction With Insulin Therapy in Patients With Type 2 Diabetes
24. The Choice of Going Public: Spin-Offs vs. Carve-Outs
25. Does the Choice of Auditor Convey Quality in an Initial Public Offering?
26. The Pricing of Initial Public Offerings: Tests of Adverse-Selection and Signaling Theories
27. Deposit Insurance and Wealth Effects: The Value of Being "Too Big to Fail"
28. An Examination of Ex-Dividend Day Stock Price Movements: The Case of Nontaxable Master Limited Partnership Distributions
29. Investing in Bankrupt Firms
30. Write-Offs As Accounting Procedures to Manage Perceptions
31. Measuring the Impact of the Safe Harbor Lease Law on Security Prices
32. Safe Harbor or Muddy Waters
33. The Evaluation by the Financial Markets of Changes in Bank Loan Loss Reserve Levels
34. Organizational Form Choice and the Valuation of Oil and Gas Producers
35. Effects of canagliflozin on myocardial infarction: a post hoc analysis of the CANVAS programme and CREDENCE trial
36. Valuation and classification of company issued cash and share-puts
37. A multicenter study of the pharmacokinetics of lisinopril in pediatric patients with hypertension
38. The Amount and Timing of Goodwill Write-Offs and Revaluations: Evidence from U.S. and U.K. Firms
39. Is the Selection of the Amortization Period for Goodwill a Strategic Choice?
40. Improving the Precision of Analysts' Earnings Forecasts by Adjusting for Predictable Bias
41. Effects of canagliflozin on myocardial infarction: a post hoc analysis of the CANVAS programme and CREDENCE trial.
42. Future Stock Performance of Oil and Gas Firms Conditional on the Imputed Value of Reserves
43. Why do firms switch underwriters
44. Insulin-like Growth Factor Binding Protein-7 Predicts Renal and Cardiovascular Outcomes in the Canagliflozin Cardiovascular Assessment Study
45. Insulin-Like Growth Factor Binding Protein 7 Predicts Renal and Cardiovascular Outcomes in the Canagliflozin Cardiovascular Assessment Study
46. The effects of combination canagliflozin and glucagon-like peptide-1 receptor agonist therapy on intermediate markers of cardiovascular risk in the CANVAS program
47. Effects of Canagliflozin on Amino-Terminal Pro–B-Type Natriuretic Peptide
48. 139-LB: The Redox Balance Predicts Both Cardiovascular (CV) and Renal Outcomes in CANVAS
49. 1123-P: Stress Cardiac Biomarkers and Adverse Cardiac Outcomes in the CANagliflozin CardioVascular Assessment Study (CANVAS)
50. Clinical outcomes with canagliflozin according to baseline body mass index: results from post hoc analyses of the CANVAS Program
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.